Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
06/2003
06/05/2003US20030106082 Transgenic stem cells, formed by dissociating blastomeres, are cultured, impregnated within surrogate; animals models; gene therapy
06/05/2003US20030105328 High effectiveness and high oral bioavailability; for example, 6-(4-Acetamidophenyl)-3-isobutyryl-5-(N-benzyl-N-methylaminomethyl)-1-(2',6'-difluorobenzyl)-1,4-dihydro-4-oxoquinoline
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105114 Methods of treatment and kits comprising a growth hormone secretagogue
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104974 Dual inhibitorsof PDE 7 and PDE 4
06/05/2003US20030104578 Secreted in yeast; storage stability; microbiocides
06/05/2003US20030104419 Method of classifying a thyroid carcinoma using differential gene expression
06/05/2003US20030101995 Dry powder inhalation system for transpulmonary administration
06/05/2003CA2471833A1 Methods of compositions for normalizing lipid levels in mammalian tissues
06/05/2003CA2468292A1 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
06/05/2003CA2468184A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003CA2468020A1 Osteopontin-related compositions and methods
06/05/2003CA2467892A1 Methods and compositions for derepression of iap-inhibited caspase
06/05/2003CA2466870A1 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003CA2466867A1 Treatment of hyperproliferative diseases using active vitamin d analogues
06/04/2003EP1316317A1 Hydrosoluble mixtures of cyproterone and/or an ester of it, processes to obtain them and uses thereof
06/04/2003EP1315835A2 Directed differentiation of embryonic cells
06/04/2003EP1315800A2 Human proteases
06/04/2003EP1315735A1 Phosphate derivatives as immunoregulatory agents
06/04/2003EP1315723A1 The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
06/04/2003EP1315722A1 Thiazolidinone nitrate salt
06/04/2003EP1315515A2 Method for treating schizophrenia and related psychoses, and the use of erythropoietin or erythropoietin derivatives for treating schizophrenic disorders and related psychoses
06/04/2003EP1315502A1 Method for treating erectile dysfunction and increasing libido in men
06/04/2003EP1252150B1 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
06/04/2003EP1214347B1 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
06/04/2003EP1196444B1 Extendin-4 conjugates and their medical use
06/04/2003EP1155014B1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them
06/04/2003EP1140945B1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
06/04/2003EP1038863B1 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
06/04/2003EP1017395A4 Method for treating premenstrual or late luteal phase syndrome
06/04/2003EP0973790B1 Estra-5(10),7-dienes with estrogenic activity
06/04/2003EP0938496B1 Heptapeptide oxytocin analogues
06/04/2003EP0775120B1 Novel pyrimidine derivatives and processes for the preparation thereof
06/04/2003EP0665752B1 Pharmaceutical compositions containing 3-beta-hydroxylated natural steroid derivatives, and use thereof
06/04/2003CN1422263A Estrogen agonist/antagonist metabolites
06/04/2003CN1422262A 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
06/04/2003CN1422246A Malonamic acids and derivatives thereof as thyroid receptor ligands
06/04/2003CN1422152A Combination of organic compound
06/04/2003CN1110327C Novel device for transdermal administration of trimegestone
06/03/2003US6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
05/2003
05/30/2003WO2003044056A2 Chemically-modified human growth hormone conjugates
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043999A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043652A2 The use of leptin in fertility
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043612A1 Micronized film-forming powder comprising an active substance
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2002079786A3 Method for identifying drugs for the treatment of type ii diabetes
05/30/2003WO2002066040A3 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
05/30/2003WO2002020090A3 Pharmaceutical compositions
05/30/2003CA2468018A1 Micronized film-forming powder comprising an active substance
05/30/2003CA2467731A1 Chemically-modified human growth hormone conjugates
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467536A1 The use of leptin in fertility
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2466491A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100587 New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100561 Treatment of insulin resistance with growth hormone secretagogues
05/29/2003US20030100543 Novel steroids containing a 14 beta ,15 beta - cyclopropane ring and a 17 alpha hydroxymethyl group; male contraceptives
05/29/2003US20030099699 Storage stable thyroxine active drug formulations and methods for their production
05/29/2003US20030099661 Compositions and methods for the treatment of immune related diseases
05/28/2003EP1313843A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313766A2 Coaster, a human coactivator of steroid receptors
05/28/2003EP1313700A1 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds
05/28/2003EP1313511A2 Testosterone ester formulation for human use
05/28/2003EP1313497A1 Use of extracts of the cassia alata plant
05/28/2003EP1313496A1 Use of a composition comprising an extract of pollen for the treatment of edema
05/28/2003EP1313495A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders
05/28/2003EP1313494A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain
05/28/2003EP1313493A1 Use of a composition comprising an extract of pollen for the treatment of irritability
05/28/2003EP1313492A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria
05/28/2003EP1313491A1 Bioactive fraction of eurycoma longifolia
05/28/2003EP1313482A1 Pharmaceutical composition and method for treating hypogonadism
05/28/2003EP1313473A2 Sustained release formulations for growth hormone secretagogues
05/28/2003EP1313461A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
05/28/2003EP1313450A1 A method of treating a systemic disease
05/28/2003EP1243275A4 Insulin-containing medicament for peroral application and method for the production thereof
05/28/2003EP1231211B1 Thiazolidinedione derivatives as antidiabetic agents
05/28/2003EP1011682B1 Hormonal contraceptive
05/28/2003EP0871457B1 Isolated stromal cells and methods of using the same
05/28/2003EP0788509B1 Therapeutic peptide derivatives
05/28/2003EP0783314B1 Compositions containing at least one glucocorticoid in combination with a pulmonary surfactant for the treatment of irds and ards
05/28/2003CN1420878A Compound with growth hormone releasing properties
05/28/2003CN1420872A Caspase inhibitors and use thereof
05/28/2003CN1420868A Process for preparation of benzamide deriv. of formula (1) and its salts
05/28/2003CN1420797A Method for improvement of islet signaling in diabetes mellitus and for its prevention
05/28/2003CN1420765A Method for chemoprevention of prostate cancer
05/28/2003CN1420762A Devices for delivery of drugs having antiprogestinic properties
05/28/2003CN1109683C 2-arylbenzo [b] thiophenes useful for treatment of estrogen deprivation syndrome
05/27/2003US6570020 Reacting 2-(3,3,3-trifluoropropyl),2-hydroxy,4a-benzyl-7-carboxy-1,2,3,4,4a,9,10,10a -octahydrophenanthrene with 2-methyl-3-(aminomethyl)pyridine to form the corresponding pyridyl-substituted amide at position 7
05/27/2003US6570002 Inhibitor of programmed cell death
05/27/2003US6569896 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
1 ... 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 ... 290